Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Zi-Hua Guo,
Saadullah Khattak,
Mohd Ahmar Rauf,
Mohammad Azam Ansari,
Mohammad N. Alomary,
Sufyan Razak,
Chang-Yong Yang,
Dong-Dong Wu,
Xin-Ying Ji
Affiliations
Zi-Hua Guo
Department of Neurology, Kaifeng Hospital of Traditional Chinese Medicine, No. 54 East Caizhengting St., Kaifeng 475000, China
Saadullah Khattak
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China
Mohd Ahmar Rauf
Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Mohammad Azam Ansari
Department of Epidemic Disease Research, Institute for Research & Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
Mohammad N. Alomary
National Centre for Biotechnology, King Abdulaziz City for Science and Technology (KACST), P.O. Box 6086, Riyadh 11442, Saudi Arabia
Sufyan Razak
Dow Medical College, John Hopkins Medical Center, School of Medicine, Baltimore, MD 21205, USA
Chang-Yong Yang
School of Nursing and Health, Henan University, Kaifeng 475004, China
Dong-Dong Wu
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China
Xin-Ying Ji
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China
Central nervous system disorders, especially neurodegenerative diseases, are a public health priority and demand a strong scientific response. Various therapy procedures have been used in the past, but their therapeutic value has been insufficient. The blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier is two of the barriers that protect the central nervous system (CNS), but are the main barriers to medicine delivery into the CNS for treating CNS disorders, such as brain tumors, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Nanotechnology-based medicinal approaches deliver valuable cargos targeting molecular and cellular processes with greater safety, efficacy, and specificity than traditional approaches. CNS diseases include a wide range of brain ailments connected to short- and long-term disability. They affect millions of people worldwide and are anticipated to become more common in the coming years. Nanotechnology-based brain therapy could solve the BBB problem. This review analyzes nanomedicine’s role in medication delivery; immunotherapy, chemotherapy, and gene therapy are combined with nanomedicines to treat CNS disorders. We also evaluated nanotechnology-based approaches for CNS disease amelioration, with the intention of stimulating the immune system by delivering medications across the BBB.
